Sjögren's syndrome comes of age

Primary Sjögren's syndrome (SS) is an autoimmune exocrine disease characterized by salivary and lacrimal gland destruction progressing to xerostomia and xerophthalmia (sicca symptoms). Nevertheless, any exocrine as well as nonexocrine organ may be involved. Dryness is not solely a result of gla...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
1999
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/28419
Acceso en línea:
https://doi.org/10.1016/S0049-0172(99)80001-8
https://repository.urosario.edu.co/handle/10336/28419
Palabra clave:
Sjögren's syndrome
Autoimmunity
Apoptosis
Muscarinic receptors
Pilocarpine
Cerimeline
Rights
License
Restringido (Acceso a grupos específicos)
id EDOCUR2_1b4c3bc9d0d6585cc986c25a8d14c221
oai_identifier_str oai:repository.urosario.edu.co:10336/28419
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 194747786009addbd1e-332e-405b-883c-38a4707fe5472020-08-28T15:48:09Z2020-08-28T15:48:09Z1999-06Primary Sjögren's syndrome (SS) is an autoimmune exocrine disease characterized by salivary and lacrimal gland destruction progressing to xerostomia and xerophthalmia (sicca symptoms). Nevertheless, any exocrine as well as nonexocrine organ may be involved. Dryness is not solely a result of glandular destruction; cytokines, autoantibodies, and other soluble factors may be also involved. We propose a two-stage model of SS pathogenesis in which the initial process seems to be increased epithelial cell apoptosis leading to autoantibody production and subsequent salivary gland lymphocytic infiltration. Treatment of SS includes education, prevention, tears and saliva substitution, exocrine glands stimulation, and immunointervention. Pilocarpine, a natural alkaloid and stimulator of muscarinic receptors in exocrine glands, is an effective agent for the treatment of sicca symptoms. Another systemic stimulatory agent to treat sicca symptoms is cevimeline, a quinuclidine derivative of acetylcholine that exhibits high affinity for the muscarinic M3 receptor which is located on lacrimal and salivary gland epithelium. Molecular understanding of the biological mechanisms that lead to tissue damage in SS may lead to newer biological treatment for this common, disabling and at times devastating illness.application/pdfhttps://doi.org/10.1016/S0049-0172(99)80001-8ISSN: 0049-0172EISSN: 1532-866Xhttps://repository.urosario.edu.co/handle/10336/28419engElsevier359No. 6355Seminars in Arthritis and RheumatismVol. 28Seminars in Arthritis and Rheumatism, ISSN: 0049-0172;EISSN: 1532-866X, Vol. 28, No. 6 (June 1999); pp. 355-359https://www.sciencedirect.com/science/article/abs/pii/S0049017299800018Restringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecSeminars in Arthritis and Rheumatisminstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURSjögren's syndromeAutoimmunityApoptosisMuscarinic receptorsPilocarpineCerimelineSjögren's syndrome comes of ageEl síndrome de Sjögren alcanza la mayoría de edadarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Anaya, Juan-ManuelTalal, Norman10336/28419oai:repository.urosario.edu.co:10336/284192021-08-13 23:12:51.744https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Sjögren's syndrome comes of age
dc.title.TranslatedTitle.spa.fl_str_mv El síndrome de Sjögren alcanza la mayoría de edad
title Sjögren's syndrome comes of age
spellingShingle Sjögren's syndrome comes of age
Sjögren's syndrome
Autoimmunity
Apoptosis
Muscarinic receptors
Pilocarpine
Cerimeline
title_short Sjögren's syndrome comes of age
title_full Sjögren's syndrome comes of age
title_fullStr Sjögren's syndrome comes of age
title_full_unstemmed Sjögren's syndrome comes of age
title_sort Sjögren's syndrome comes of age
dc.subject.keyword.spa.fl_str_mv Sjögren's syndrome
Autoimmunity
Apoptosis
Muscarinic receptors
Pilocarpine
Cerimeline
topic Sjögren's syndrome
Autoimmunity
Apoptosis
Muscarinic receptors
Pilocarpine
Cerimeline
description Primary Sjögren's syndrome (SS) is an autoimmune exocrine disease characterized by salivary and lacrimal gland destruction progressing to xerostomia and xerophthalmia (sicca symptoms). Nevertheless, any exocrine as well as nonexocrine organ may be involved. Dryness is not solely a result of glandular destruction; cytokines, autoantibodies, and other soluble factors may be also involved. We propose a two-stage model of SS pathogenesis in which the initial process seems to be increased epithelial cell apoptosis leading to autoantibody production and subsequent salivary gland lymphocytic infiltration. Treatment of SS includes education, prevention, tears and saliva substitution, exocrine glands stimulation, and immunointervention. Pilocarpine, a natural alkaloid and stimulator of muscarinic receptors in exocrine glands, is an effective agent for the treatment of sicca symptoms. Another systemic stimulatory agent to treat sicca symptoms is cevimeline, a quinuclidine derivative of acetylcholine that exhibits high affinity for the muscarinic M3 receptor which is located on lacrimal and salivary gland epithelium. Molecular understanding of the biological mechanisms that lead to tissue damage in SS may lead to newer biological treatment for this common, disabling and at times devastating illness.
publishDate 1999
dc.date.created.spa.fl_str_mv 1999-06
dc.date.accessioned.none.fl_str_mv 2020-08-28T15:48:09Z
dc.date.available.none.fl_str_mv 2020-08-28T15:48:09Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/S0049-0172(99)80001-8
dc.identifier.issn.none.fl_str_mv ISSN: 0049-0172
EISSN: 1532-866X
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/28419
url https://doi.org/10.1016/S0049-0172(99)80001-8
https://repository.urosario.edu.co/handle/10336/28419
identifier_str_mv ISSN: 0049-0172
EISSN: 1532-866X
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 359
dc.relation.citationIssue.none.fl_str_mv No. 6
dc.relation.citationStartPage.none.fl_str_mv 355
dc.relation.citationTitle.none.fl_str_mv Seminars in Arthritis and Rheumatism
dc.relation.citationVolume.none.fl_str_mv Vol. 28
dc.relation.ispartof.spa.fl_str_mv Seminars in Arthritis and Rheumatism, ISSN: 0049-0172;EISSN: 1532-866X, Vol. 28, No. 6 (June 1999); pp. 355-359
dc.relation.uri.spa.fl_str_mv https://www.sciencedirect.com/science/article/abs/pii/S0049017299800018
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.rights.acceso.spa.fl_str_mv Restringido (Acceso a grupos específicos)
rights_invalid_str_mv Restringido (Acceso a grupos específicos)
http://purl.org/coar/access_right/c_16ec
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.source.spa.fl_str_mv Seminars in Arthritis and Rheumatism
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1808391012484120576